Three-statement Excel model · 18 quarters and 4 fiscal years of history · 10 quarters and 5 fiscal years of projections
About the JNJ model
This three-statement Excel model covers Johnson & Johnson (JNJ): its income statement, balance sheet and cash flow statement. It holds 18 quarters and 4 fiscal years of history and 10 quarters and 5 fiscal years of projections.
Projected revenue is built from KPI drivers: Ten filed franchises grown off the same quarter a year earlier; segment totals sum them, and fiscal 2026's 53rd week sits in the 4Q rates, across 2 segments.
Beyond the income statement, the workbook has these sections: KPI Drivers, Balance Sheet and Cash Flow Statement.
Model thesis: Four years, not five: continuing-ops quarters stop at 1Q22, so the window starts where the Kenvue restatement does rather than opening a 16% basis seam
On October 19, 2026, the model passed checks C13 (every subtotal reconciles to the reported figure at $0), C14 (every projected revenue cell traces to a KPI driver row) and C15 (each driver ends in a rate, a count or a historical anchor, never a typed-in projected dollar level). It was last updated September 22, 2026.
Income statement preview
Columns FY2023–FY2025 are actual results and FY26E–FY28E are our estimates. Figures were recalculated in Excel on September 28, 2026. Dollars in millions, except per share.
| Income Statement | ||||||
|---|---|---|---|---|---|---|
| Actual | Estimate | |||||
| FY2023 | FY2024 | FY2025 | FY26E | FY27E | FY28E | |
| Immunology | $18,052.0 | $17,828.0 | $15,728.0 | $15,467.4 | $16,476.8 | $17,630.2 |
| Infectious Diseases | 4,418.0 | 3,396.0 | 3,241.0 | 3,214.3 | 3,117.8 | 3,024.3 |
| Neuroscience | 7,140.0 | 7,115.0 | 7,837.0 | 9,158.7 | 10,093.7 | 10,901.1 |
| Oncology | 17,661.0 | 20,781.0 | 25,380.0 | 29,646.9 | 33,266.9 | 36,926.2 |
| Pulmonary Hypertension | 3,815.0 | 4,282.0 | 4,437.0 | 4,629.2 | 4,680.4 | 4,680.4 |
| Cardiovascular / Metabolism / Other | 3,671.0 | 3,562.0 | 3,778.0 | 3,517.6 | 3,376.9 | 3,241.8 |
| Franchise Rounding (Innovative Medicine) | 2.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Innovative Medicine | $54,759.0 | $56,964.0 | $60,401.0 | $65,634.1 | $71,012.5 | $76,404.1 |
| Cardiovascular | 6,350.0 | 7,707.0 | 8,928.0 | 9,485.8 | 10,136.7 | 10,947.7 |
| Orthopaedics | 8,942.0 | 9,158.0 | 9,258.0 | 9,750.2 | 10,101.5 | 10,455.0 |
| Surgery | 10,037.0 | 9,845.0 | 10,137.0 | 10,558.5 | 10,886.4 | 11,267.4 |
| Vision | 5,072.0 | 5,146.0 | 5,468.0 | 5,805.4 | 6,087.0 | 6,391.3 |
| Franchise Rounding (MedTech) | (1.0) | 1.0 | 1.0 | 0.0 | 0.0 | 0.0 |
| MedTech | $30,400.0 | $31,857.0 | $33,792.0 | $35,599.9 | $37,211.5 | $39,061.4 |
| Total Revenue | $85,159.0 | $88,821.0 | $94,193.0 | $101,234.1 | $108,224.1 | $115,465.5 |
| Less: Cost of Products Sold | ($26,553.0) | ($27,471.0) | ($30,256.0) | ($32,451.0) | ($34,314.7) | ($36,263.9) |
| Gross Profit | $58,606.0 | $61,350.0 | $63,937.0 | $68,783.1 | $73,909.4 | $79,201.6 |
| Less: Selling, Marketing and Administrative Expenses | ($21,512.0) | ($22,869.0) | ($23,676.0) | ($25,965.2) | ($27,562.9) | ($29,176.4) |
| Less: Research and Development Expense | (15,085.0) | (17,232.0) | (14,665.0) | (15,489.5) | (16,525.5) | (17,516.0) |
| Less: In-Process Research and Development Impairments | (313.0) | (211.0) | (81.0) | (87.9) | (108.2) | (115.5) |
| Less: Restructuring | (489.0) | (234.0) | (228.0) | (169.7) | (216.4) | (230.9) |
| Total Operating Expenses | ($37,399.0) | ($40,546.0) | ($38,650.0) | ($41,712.4) | ($44,413.1) | ($47,038.8) |
| Operating Income | $21,207.0 | $20,804.0 | $25,287.0 | $27,070.7 | $29,496.3 | $32,162.8 |
| Interest Income | $1,261.0 | $1,332.0 | $1,056.0 | $888.8 | $919.9 | $981.5 |
| Less: Interest Expense, Net of Portion Capitalized | (772.0) | (755.0) | (971.0) | (1,123.5) | (1,190.5) | (1,270.1) |
| Other Income / (Expense), Net | (6,634.0) | (4,694.0) | 7,209.0 | (1,247.3) | (1,298.7) | (1,385.6) |
| Earnings Before Provision for Taxes on Income | $15,062.0 | $16,687.0 | $32,581.0 | $25,588.7 | $27,927.0 | $30,488.6 |
| Less: Provision for Taxes on Income | ($1,736.0) | ($2,621.0) | ($5,777.0) | ($4,217.0) | ($4,887.2) | ($5,335.5) |
| Net Earnings from Continuing Operations | $13,326.0 | $14,066.0 | $26,804.0 | $21,371.7 | $23,039.8 | $25,153.1 |
| Net Earnings from Discontinued Operations, Net of Tax | 21,827.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | $35,153.0 | $14,066.0 | $26,804.0 | $21,371.7 | $23,039.8 | $25,153.1 |
| Ratios & Assumptions | ||||||
| Gross Margin | 68.8% | 69.1% | 67.9% | 67.9% | 68.3% | 68.6% |
| Incremental Gross Margin | 62.1% | 74.9% | 48.2% | 68.8% | 73.3% | 73.1% |
| Operating Margin | 24.9% | 23.4% | 26.8% | 26.7% | 27.3% | 27.9% |
| Continuing Operations Net Margin | 15.6% | 15.8% | 28.5% | 21.1% | 21.3% | 21.8% |
| Net Margin | 41.3% | 15.8% | 28.5% | 21.1% | 21.3% | 21.8% |
The full workbook adds 18 historical and 10 projected quarters, plus KPI Drivers · Balance Sheet · Cash Flow Statement — every subtotal a live formula, every projection traced to a driver.
Johnson & Johnson research
Aardvark Labs Capital Research has published 6 reports on Johnson & Johnson (JNJ). The latest is the Q3 2026 Earnings Recap, published October 19, 2026, rated Hold.
Pharma Carries the Quarter and Talc Finally Has a Price, but MedTech Slows for a Third Straight Quarter: Maintaining Hold as Fair Value Rolls to $230–260
Methodology
Every projected revenue cell traces to a KPI/driver row (C14). Terminal driver cells are rates, counts, or historical anchors — never typed-in projected dollar levels (C15). Every subtotal-vs-reported reconciliation row ties to $0 (C13). Each model is written per-ticker against its actual schema — no cloning, no level-input shortcuts.